Download CV. Aurora, CO University of Colorado Anschutz Medical Campus. Research Interests My research interests are primarily focused on understanding and overcoming tumor induced immune suppression. Along with my research colleagues, we have active investigations intent on discovering how tumors shut down the immune response to the cancer, and more importantly, find ways to prevent this from occurring.
I lead investigator initiated clinical trials developing treatments that enhance a patient's own immune response against tumors. In addition, I work closely with other cancer researchers in developing and applying targeted and immunotherapies therapies for GI tumors, Melanoma and Sarcoma. Ann Surg Oncol. Cancers Basel. Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.
Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampullary and pancreatic adenocarcinoma.
Am J Surg. Cancer Res Commun. Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling. Int J Cancer. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death Dis. J Surg Res. National trends in technique use for esophagectomy: Does primary surgeon specialty matter?.
Dysfunctional states of unconventional T-cell subsets in cancer. J Leukoc Biol. Pigment Cell Melanoma Res. Mol Cell Oncol. Sci Immunol. The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism to impair anti-tumor immunity.
